BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24999743)

  • 1. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.
    Syed BM; Green AR; Nolan CC; Morgan DA; Ellis IO; Cheung KL
    PLoS One; 2014; 9(7):e100573. PubMed ID: 24999743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients.
    Syed BM; Green AR; Ellis IO; Cheung KL
    Ann Oncol; 2014 Apr; 25(4):837-842. PubMed ID: 24667716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts.
    Syed BM; Green AR; Paish EC; Soria D; Garibaldi J; Morgan L; Morgan DA; Ellis IO; Cheung KL
    Br J Cancer; 2013 Mar; 108(5):1042-51. PubMed ID: 23462719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.
    Syed BM; Green AR; Morgan DAL; Ellis IO; Cheung KL
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30696074
    [No Abstract]   [Full Text] [Related]  

  • 5. Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.
    Syed BM; Morgan D; Setty T; Green AR; Paish EC; Ellis IO; Cheung KL
    PLoS One; 2017; 12(12):e0188528. PubMed ID: 29284000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
    PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
    Treré D; Brighenti E; Donati G; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Derenzini M
    Ann Oncol; 2009 Nov; 20(11):1818-23. PubMed ID: 19556322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
    Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
    Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of primary breast cancer in older women beyond routine biomarkers.
    Parks RM; Alfarsi LH; Green AR; Cheung KL
    Breast Cancer; 2021 Sep; 28(5):991-1001. PubMed ID: 34165702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.
    Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA
    PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
    Zhu X; Chen L; Huang B; Wang Y; Ji L; Wu J; Di G; Liu G; Yu K; Shao Z; Wang Z
    Sci Rep; 2020 Jan; 10(1):225. PubMed ID: 31937819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
    Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
    Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Tzikas AK; Nemes S; Linderholm BK
    Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
    Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
    Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
    Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
    World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
    Choi YL; Oh E; Park S; Kim Y; Park YH; Song K; Cho EY; Hong YC; Choi JS; Lee JE; Kim JH; Nam SJ; Im YH; Yang JH; Shin YK
    BMC Cancer; 2010 Sep; 10():507. PubMed ID: 20860845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.